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The presentation of Non Hodgkin’s Lymphoma (NHL) may vary in relation to ethnicity or environmental effects. The
objective of our study was to characterize NHL among the Negev Bedouin population, compared to the Jewish
population.
Retrospective data were collected for 45 Bedouin and 45 Jewish patients who were treated at Soroka University
Medical Center between 1990 and 2007.
Upon diagnosis, rates of aggressive NHL types, involvement of extra-lymphatic organs, as well as mean LDH were
higher among Bedouin. Treatment response was poorer among the Bedouin: overall survival and disease-free
survival were higher among Jews (mean of 145 and 168 months, respectively, compared with 70 and 45 months,
respectively, among Bedouin; p < 0.01 for both).
In summary, disease aggressiveness and poor response to treatment among the Negev Bedouin may shed some
light on the pathogenicity of NHL and may indicate a need for more aggressive treatment in different ethnic
groups.
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Non Hodgkin’s Lymphoma (NHL) is a heterogeneous
group of lymphoid malignancies that differ in cell source
and histology, as well as clinical characteristics, prognosis,
and response to treatment. A worldwide significant increase
in the incidence of the disease has been observed in the last
forty years (Greenlee et al. 2007; a). The Bedouin population
in the Negev shows characteristics of Hodgkin Lymphoma
that are different than those in the Jewish population
(Levy et al. 2002). However, there is no knowledge regard-
ing NHL characteristics at presentation, its response to
treatment, and course in Bedouins in the Negev.
The Bedouin population in the Negev lives in permanent
towns and small unrecognized villages. Due to the natural
loss of livelihood, based in the past on agriculture and
pasturing livestock, along with the lack of infrastructure* Correspondence: etail@clalit.org.il
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in any medium, provided the original work is pand industry in the Bedouin towns, the Bedouin population
is in the lowest level of the socioeconomic scale in Israel b.
Cure of NHL is largely affected by characteristics of the
disease at diagnosis, which can be expressed using the
International Prognostic Index (IPI) (The International
Non-Hodgkin’s Lymphoma Prognostic Factors Project
1993). Another important factor is the ability to tolerate
aggressive treatment, which requires a high level of com-
pliance and appropriate living conditions and sanitation,
which are unavailable in many Bedouin villages.
A review of the literature suggests that although some
characteristics of NHL were studied among Arab popula-
tions (Ameen et al. 2010; Castella et al. 2001; Cohen et al.
1989), clinical and epidemiological characteristics and the
response to treatment of NHL among the Bedouin popu-
lation have not been investigated thoroughly. A study that
examined the clinical and epidemiological characteristics
of Jewish and Bedouin patients with Hodgkin’s Lymphoma
in southern Israel showed that Bedouin response to treat-
ment is poorer compared to that of Jews (Levy et al. 2002).
Another study showed a link between residential proximityopen access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 2 Comparison of histological subtypes at diagnosis
between Bedouins and Jews
Bedouins Jews
No. % No. %
Follicular 2 4.4 12 26.7
Marginal zone 3 6.6 2 4.4
Diffuse large B-cell 28 62.2 27 60
Mantle cell 2 4.4 1 2.2
Peripheral T-cell 5 11.1 - -
Burkitt 2 4.4 1 2.2
T-cell lymphoblastic 3 6.7 2 4.4
Table 3 Comparison of disease characteristics at diagnosis
between Bedouins and Jews
Bedouins Jews p value
No. % No. %
All histological subtypes
Stage 4 18 40 11 24.4 0.347
Extranodal involvement 7 15.6 1 2.2 0.026
Stomach 2
Pleura 2
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of NHL (Dreiher et al. 2005). Ramat Hovav is a central
industrial zone with 17 chemical factories and a toxic
waste treatment site that may contaminate the environ-
ment with chemicals such as phenoxyacetic acid, organic
solvents, triazines, and carbamates. While there is only a
small Jewish population residing close to Ramat Hovav,
a significant part of the Bedouin population resides
close to it, and it is important to study the incidence of
NHL among them.
Soroka University Medical Center is a tertiary center
providing medical care to a major part of the Bedouin
population in Israel. The purpose of this study was to
characterize NHL in terms of the aggressiveness of the
disease and its response to treatment in the Bedouin
population compared to the Jewish population in the
south of Israel.
Results
Both study groups included 45 patients, of whom there
were 21 men and 24 women. The mean age at diagnosis
was 48 years (Table 1). A comparison of demographic
and socioeconomic status between the groups showed
Bedouin patients had larger families, with a mean of seven
children compared to two among Jewish families. All 45
Jewish patients reside in houses. In contrast, among the
Bedouin only 25 (55.6%) of the patients reside in houses,
and 7 (15.5%) of them live in a hut or tent. In 13 Bedouin
patients it was impossible to locate a residential address,
which suggests that they lived in unrecognized villages. It
was impossible to evaluate from the medical records the
degree of chemical exposure and the dietary habits in both
groups.
The characteristics of NHL at diagnosis are worse among
Bedouins than Jews (Tables 2 and 3). The incidence of
aggressive NHL types is higher among Bedouin: 22% of theTable 1 Comparison of demographic features between
Bedouin and Jewish patients
Demographic Jews Bedouins p
valueno. % no. %
Gender
Female 24 53.33 24 53.33
Male 21 46.67 21 46.67
Mean age at diagnosis (years) 48.7 47.6 0.843
Mean number of children 2.4 7.1 <0.001
Housing form
House 45 100 25 55.6
Shed 0 6 13.3
Tent 0 1 2.2
Unknown 0 13 28.9Bedouin compared to 9% of the Jewish patients (p = 0.03).
Indolent lymphoma was found in 31.1% of the Jewish
group, whereas it was found in only 11% of the Bedouin
group. Rate of extra-nodal involvement is also higher
among Bedouins (15%) compared with Jews (2%). The
mean Lactate Dehydrogenase (LDH) level at diagnosis is
higher among Bedouins (773 U/L) compared to a lower
level (512 U/L) among Jews (p = 0.008). When comparing
functional status according to the ECOG performance
status between groups, the rate of patients in ECOG 3–4
at diagnosis is higher among Bedouin (24.4%) than JewishLiver 2
Lung 1
CNS 1
Mean LDH (U/L) 773.92 512.15 0.008
ECOG 1–2 34 75.6 40 95.2
ECOG 3–4 11 24.4 2 4.8 0.01
Positive/tested
Hepatitis B 3/11 0/11
Hepatitis C 0/7 0/11 0.214
HIV 0/4 0/4
DLBCL subtype
Mean LDH (U/L) 827.07 538.17 0.019
Mean IPI 2.26 1.41 0.011
ECOG 1–2 22 73.3 25 96.2 0.022
ECOG 3–4 8 26.7 1 3.8
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Bedouins were diagnosed at stage 4 (40%) compared
with Jews (24.4%), but the difference is not statistically
significant.
Patients from both groups were treated similarly. The
patients with Diffuse large B cell lymphoma (DLBCL)
were treated with chemotherapeutic drugs alone–CHOP
(Cyclophosphamide Hydrochloride Doxorubicin, Oncovin,
prednisone) protocol until 2000 and R (Rituximab)-CHOP
since 2000. The other patients were treated according
to the acceptable chemotherapy protocol at the time of
diagnosis with no difference between Jewish and Bedouin
patients. The follow-up period for OS and DFS evaluation
was the same for the two groups.
Comparing the response to treatment (Table 4), Jewish
patients achieved a higher rate of CR (80%) compared
with Bedouin patients (65.8%). In addition, the rate of
relapse among patients who achieved remission is higher
among Bedouins than Jews, 34.3% and 18.9%, respectively.
This difference is not statistically significant.
The mean OS for all patients in our series was 122 months
(95% CI: 99–145 months). More than half of all patients
were alive at the end of the follow-up period. The
mean DFS for all patients was 105 months (95% CI:
83–129 months) and median DFS was 76 months (95%
CI: 39–113 months).
Comparison of OS between the two study groups
(Figure 1 and Table 4) shows OS to be lower among
Bedouin. Mean OS among Jews was 168 months (95% CI:
144–192 months), compared to 70 months in Bedouin
(95% CI: 43–96 months). The difference is statistically sig-
nificant (p < 0.001).
When comparing DFS between the study groups (Figure 2
and Table 4), it was found to be significantly higher in Jews,










Mean overall survival (months) 70 (95% CI: 43
Mean disease-free survival (months) 57 (95% CI: 32
DLBCL patients
Mean overall survival (months) 88 (95% CI:54–
Mean disease-free survival (months) 75 (95% CI:41–compared to 57 months (95% CI: 32–83 months) in
Bedouins.
Since we found a different distribution of pathologic
diagnoses between Jews and Bedouins, we assumed that
this had an effect on other characteristics of the disease at
diagnosis (such as performance status, stage of disease, IPI
score). To test whether differences in the characteristics
of Lymphoma exist between study groups regardless of
pathology type, we compared a subgroup of patients with
the same pathology. We compared patients diagnosed
with DLBCL, who comprise 60% of patients in this series
(Table 2). The differences in expression of the disease
(IPI, LDH, performance status) were persistent between
the two sub-groups, being significantly worse among
the Bedouin. Comparison of OS and DFS between Jews
and Bedouin with DLBCL yielded similar results to those
for all patients. OS and DFS were lower among the
Bedouin, with borderline significance (Table 4, Figures 3
and 4).
Discussion
In this study we found that NHL has different characteris-
tics among the Bedouin compared to Jewish population in
the south of Israel. Disease characteristics at diagnosis tend
to be worse among the Bedouin. Extra-nodal involvement,
high LDH, and poor performance status are more frequent
among the Bedouin. Advanced disease at presentation
is more common among the Bedouin, but the difference is
not significant. The incidence of aggressive lymphomas is
also significantly higher among Bedouin. Jews have a higher
rate of follicular lymphoma whereas the Bedouins have
higher rates of T-cell Lymphoma and other aggressive
pathologies.
Similar findings were found in a study conducted at





7.9 3 7.5 0.290
34.3 7 18.9
65.7 30 81.1 0.139
–96) 168 (95% CI: 144–192) <0.001
–83) 145 (95% CI: 116–175) <0.001
122) 153 (95% CI:118–188) 0.054
108) 136 (95% CI:98–174) 0.046
Figure 1 Overall survival in months by ethnicity (Jewish versus Bedouin).
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Bedouin and other populations in southern Israel. The
characteristics of the disease at diagnosis were different
between groups. Histology of mixed cellularity and more
advanced disease at diagnosis were more common among
the Bedouin. Results for treatment response and prognosis
were also similar to those seen in the current study.Figure 2 Disease-free survival in months by ethnicity (Jewish versus BBedouin had a higher rate of resistant disease, and lower
overall survival and survival without disease.
There are several possible explanations for these differ-
ences in the presentation of Lymphoma among Bedouin
in this study.
Lower availability and reduced use of medical services
among the Bedouin result in the diagnosis of Lymphomaedouin).
Figure 3 Overall survival by ethnicity (Jewish versus Bedouin), only among patients with Diffuse Large B-Cell Lymphoma.
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level, low awareness of preventive medicine, and lack of
access to medical service.
It also may be possible that exposure to chemical con-
taminants plays a role in the development of Lymphoma.
As noted above, there is a study that examined the relation-
ship between residential proximity to Ramat Hovav and
incidence of NHL (Dreiher et al. 2005). The study found
that living near the Ramat Hovav site constitutes a riskFigure 4 Disease-free survival in months by ethnicity (Jewish versus Befactor for morbidity in NHL. The study was conducted
among a population that included mostly an urban Jewish
population. Presumably Bedouin, who live even closer
to the site, are more exposed to these toxic substances.
However, it is impossible to estimate with certainty how
many Bedouin who were included in our study have been
exposed to environmental pollutants near their residence.
An important factor in development of some malignant
disease is nutrition habits. Two studies (Fraser et al. 2001,douin), only among patients with Diffuse Large B-Cell Lymphoma.
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Bedouin populations in southern Israel. Bedouin nutrition
was found to be characterized with lower intake of fat,
cholesterol, and protein and higher intake of carbohydrates
and fibers. However, there are no public data regarding the
influence of this diet on NHL severity or survival.
It might be that genetic and geographic differences
play a role in the differences between the groups, mainly
in the histological type of the Lymphoma. T-cell Lymph-
omas, for instance, are more common in Asia, while the
B-cell Lymphomas are more common in Western coun-
tries (Rüdiger et al. 2002).
A study from the north of Israel showed higher
prevalence of nodular lymphoma in Ashkenazi Jews
and higher prevalence of extranodal lymphoma in Arabs
and non-Ashkenazi Jews (Cohen et al. 1989). A study that
evaluated frequencies of NHL subtype in Kuwait found a
higher prevalence of DLBCL and extranodal presentation
compared to the Western world (Ameen et al. 2010). A
study from Jordan classified 111 cases of NHL from two
major medical centers (Almasri et al. 2004). Aggressive
lymphoma accounted for the majority of NHL, while
indolent lymphomas were rare and accounted for less
than 15% of all NHLs. Our results are similar to these
results. Higher incidence of aggressive lymphomas such
as Burkitt’s and Lymphoblastic lymphoma in the Bedouin
as in other Arab populations may have a common
mechanism. This may indicate genetic and environmental
factors that are responsible for the greater presentation of
aggressive histological subtypes in Bedouin compared to
the Jewish population. Because of the small number of
patients in this study, we cannot evaluate accurately
how this study represents the distribution of histological
subtypes of Lymphoma among all the population, and
especially among the Jewish population in Israel.
Our results show decreased response to treatment
among the Bedouins. OS and DFS are significantly better
among Jews compared to Bedouins. These results can
be explained by two main reasons: more aggressive and
advanced disease at diagnosis and lower compliance with
treatment compared to Jewish patients, partly because of
poor living conditions. Two studies from the south of
Israel (Tamir et al. 2007; Cohen et al. 2008) found that
low compliance with drug therapy and follow-up tests,
and non-attendance to the clinic are major problems in
the Bedouin population. These findings may suggest that
an important reason for lower response rate of Bedouin to
chemotherapy is poor compliance.
Due to the different distribution of histological subtypes
between the groups, and the influence of histology on
prognosis, we decided to test whether differences between
populations are maintained when comparing subgroups of
patients with identical pathology. The characteristics of
DLBCL at presentation are significantly worse amongBedouins (mean LDH was higher, poorer performance
status, and higher IPI). Similarly, the survival was lower
among the Bedouins, with borderline significance.
There are several limitations to this study. There was no
randomization in selecting populations. The study group
included all the Bedouin patients who were found suitable
for inclusion. The comparison group was selected ran-
domly by matching age, sex, and year of diagnosis to
those of the study group. This method may have created
selection bias. We do not know whether the comparison
group represents the entire Jewish population of NHL
patients in the Negev. We might have found a higher
rate of aggressive lymphoma if we reviewed all records
of Jewish NHL patients. In addition, we do not know
whether there is a difference in the age of lymphoma
onset between the two populations.
As is known, the characteristics of NHL at diagnosis
are predictors of the response to treatment. In the current
study we found that NHL indices among the Bedouin at
diagnosis were worse, in accordance with lower response
rate to treatment and lower survival. Because we did not
compare response to treatment in patients with the same
IPI, we cannot determine whether the lower survival rate
among the Bedouin is due to different characteristics of
the lymphoma at diagnosis or whether the difference may
also depend on other factors affecting the course of the
disease. This comparison could not be done due to the
small size of the sample.
In summary, NHL has different characteristics among
the Bedouins in the Negev compared to Jews. Among the
Bedouins, the disease tends to emerge in later stages, with a
higher IPI and more aggressive appearance. The response to
treatment and survival rate is lower among the Bedouins.
The inverse relationship between socioeconomic level
and morbidity and mortality is known for many diseases.
Our study results are compatible with this finding.
Authorities should invest in establishing a medical infra-
structure available to this population, together with an
educational program to raise awareness for early detection
and treatment of diseases. Medical staff should be aware
of the difficulties for parts of the Bedouin population in
approaching medical services. This requires attention and
effort, but will certainly increase the number of patients
diagnosed at the initial stages of disease. As the availability
of medical care and compliance of this population to
treatment will increase as a result of education, we hope
that the outcome of treatment will also improve.
Methods
A retrospective study was conducted. Data for all Bedouin
patients diagnosed with NHL and treated at Soroka
University Medical Center between 1990 and 2007 was
collected and compared to data of a group of Jewish
patients from the same region treated in our center. The
Levi et al. SpringerPlus 2013, 2:672 Page 7 of 7
http://www.springerplus.com/content/2/1/672study was approved by the Institutional Review Board of
Soroka University Medical Center.
Patients (Bedouin and Jewish) were identified through
the Israel Ministry of Health Cancer Registry. The study
group included all Bedouin patients with a histological
diagnosis of NHL, over 18 years-of-age at diagnosis,
treated and followed at Soroka University Medical Center,
and with accessible medical records. Forty-five Bedouin
patients met the inclusion criteria. For each Bedouin
patient, a Jewish patient was matched for sex, age (±2 years),
and year of diagnosis (±2 years). In cases where there was
more than one possible control, the final control was
selected randomly. For each patient we retrieved clinical,
laboratory, and imaging data at the time of diagnosis, and
the response to treatment. The two groups were compared
according to clinical and laboratory characteristics, ag-
gressiveness, and response to treatment. Aggressiveness
was categorized according to the histological sub-type
of NHL. Burkitt’s lymphoma, Lymphoblastic lymphoma,
T cell lymphoma, and Mantle cell lymphoma were
defined as aggressive lymphomas. DLBCL was defined
as intermediate grade lymphoma, and marginal zone
lymphoma and follicular lymphoma were defined as
low grade lymphomas.
Response to treatment was defined by the rate of
complete remission (CR), partial remission (PR), disease-
free survival (DFS), and overall survival (OS). Treatment
response was assessed according to the International
Working Group criteria published in 1999 (Ceason et al.
1999). A CR was defined as the disappearance of all previ-
ously measurable lesions and the absence of any new tumor
lesions. PR was defined as a decrease of at least 50% of each
lesion. Progressive disease or relapse was defined as more
than 50% increase of at least one lesion, or the presence of
newly developed lesions.
Statistical analysis
For comparison of the aggressiveness variables between
the study groups, we calculated statistical significance using
chi-square test for categorical variables and t-test for
continuous variables. We calculated overall and disease-
free survival by the Kaplan-Meier method and compared
Bedouin and Jewish patients using Log-rank test. All
analyses were done with SPSS software, version 15.0.
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municipalities by socio-economic index, ranking and cluster
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